The Efficient Global Optimization(EGO)algorithm has been widely used in the numerical design optimization of engineering systems.However,the need for an uncertainty estimator limits the selection of a surrogate model....The Efficient Global Optimization(EGO)algorithm has been widely used in the numerical design optimization of engineering systems.However,the need for an uncertainty estimator limits the selection of a surrogate model.In this paper,a Sequential Ensemble Optimization(SEO)algorithm based on the ensemble model is proposed.In the proposed algorithm,there is no limitation on the selection of an individual surrogate model.Specifically,the SEO is built based on the EGO by extending the EGO algorithm so that it can be used in combination with the ensemble model.Also,a new uncertainty estimator for any surrogate model named the General Uncertainty Estimator(GUE)is proposed.The performance of the proposed SEO algorithm is verified by the simulations using ten well-known mathematical functions with varying dimensions.The results show that the proposed SEO algorithm performs better than the traditional EGO algorithm in terms of both the final optimization results and the convergence rate.Further,the proposed algorithm is applied to the global optimization control for turbo-fan engine acceleration schedule design.展开更多
AIM: To establish the safety and efficacy of an indigenously developed r-hepatitis B vaccine using an accelerated schedule and to highlight the social awareness and commitment in preventing the spreading of hepatitis ...AIM: To establish the safety and efficacy of an indigenously developed r-hepatitis B vaccine using an accelerated schedule and to highlight the social awareness and commitment in preventing the spreading of hepatitis B virus infection. METHODS: The study was a multicentric, double blind, randomized (3:1) study using three doses of vaccine immunization schedule (20μg for those above 10 years old and 10 μg for those below 10 years old) on d 0, 30 and 60. One hundred and sixty-six subjects were enrolled (87 males and 76 females aged 5-35 years). The main outcome measure was assessment of immunogenicity and safety. RESULTS: A 100% seroconversion response was observed on the 30th d after the 1st injection in both the experimental groups. The sero-protection data reported a 41.2-65.6% response on the 30th d after the 1st injection and reached 100% on the 60th d. Descriptive statistical analysis showed a geometric mean titer value of 13.77 mIU/mL in the test (BEVAC) group and 10.95 mlU/mL in the commercial control (ENGERIX-B) group on the 30th d after the 1st injection. The response on the 60th d showed a geometric mean titre value (GMT) of 519.84 mlU/mL in the BEVAC group and 475.46 mlU/mL in the ENGERIX-B group. On the 90th d, the antibody titer response was observed to be 2627.58 mlU/mL in the BEVAC group and 2272.72 mlU/mL in the ENGERIX-B group. Two subjects in each group experienced pains at injection site after the first vaccination. A total of six subjects in both groups experienced a solicited adverse reaction, which included pains, swelling and redness at the injection site, three subjects in the group-B had a pain at the injection site after the third dose. No other serious adverse events occurred and no dose-related local or general symptoms were observed during the study. CONCLUSION: The vaccine is safe, efficacious and immunogenic in comparison with the well documented ENGERIX-B.展开更多
基金the financial support of the National Natural Science Foundation of China(Nos.52076180,51876176 and 51906204)National Science and Technology Major Project,China(No.2017-I0001-0001)。
文摘The Efficient Global Optimization(EGO)algorithm has been widely used in the numerical design optimization of engineering systems.However,the need for an uncertainty estimator limits the selection of a surrogate model.In this paper,a Sequential Ensemble Optimization(SEO)algorithm based on the ensemble model is proposed.In the proposed algorithm,there is no limitation on the selection of an individual surrogate model.Specifically,the SEO is built based on the EGO by extending the EGO algorithm so that it can be used in combination with the ensemble model.Also,a new uncertainty estimator for any surrogate model named the General Uncertainty Estimator(GUE)is proposed.The performance of the proposed SEO algorithm is verified by the simulations using ten well-known mathematical functions with varying dimensions.The results show that the proposed SEO algorithm performs better than the traditional EGO algorithm in terms of both the final optimization results and the convergence rate.Further,the proposed algorithm is applied to the global optimization control for turbo-fan engine acceleration schedule design.
基金Supported by the Biological E Limited, Hyderabad, India
文摘AIM: To establish the safety and efficacy of an indigenously developed r-hepatitis B vaccine using an accelerated schedule and to highlight the social awareness and commitment in preventing the spreading of hepatitis B virus infection. METHODS: The study was a multicentric, double blind, randomized (3:1) study using three doses of vaccine immunization schedule (20μg for those above 10 years old and 10 μg for those below 10 years old) on d 0, 30 and 60. One hundred and sixty-six subjects were enrolled (87 males and 76 females aged 5-35 years). The main outcome measure was assessment of immunogenicity and safety. RESULTS: A 100% seroconversion response was observed on the 30th d after the 1st injection in both the experimental groups. The sero-protection data reported a 41.2-65.6% response on the 30th d after the 1st injection and reached 100% on the 60th d. Descriptive statistical analysis showed a geometric mean titer value of 13.77 mIU/mL in the test (BEVAC) group and 10.95 mlU/mL in the commercial control (ENGERIX-B) group on the 30th d after the 1st injection. The response on the 60th d showed a geometric mean titre value (GMT) of 519.84 mlU/mL in the BEVAC group and 475.46 mlU/mL in the ENGERIX-B group. On the 90th d, the antibody titer response was observed to be 2627.58 mlU/mL in the BEVAC group and 2272.72 mlU/mL in the ENGERIX-B group. Two subjects in each group experienced pains at injection site after the first vaccination. A total of six subjects in both groups experienced a solicited adverse reaction, which included pains, swelling and redness at the injection site, three subjects in the group-B had a pain at the injection site after the third dose. No other serious adverse events occurred and no dose-related local or general symptoms were observed during the study. CONCLUSION: The vaccine is safe, efficacious and immunogenic in comparison with the well documented ENGERIX-B.
